PharmEnable announces multi-target collaboration with Denali Therapeutics in neurodegenerative disease

  • The strategic collaboration aims to accelerate drug discovery in neurodegenerative disease
  • Joint research programmes against multiple undisclosed targets to be initiated over the next two years
  • PharmEnable to receive an upfront cash payment and potential milestone payments

PharmEnable is delighted to announce a collaboration with Denali Therapeutics, a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases.

In this collaboration, PharmEnable will leverage its proprietary AI drug discovery platform with Denali’s expertise in delivery across the BBB and neurodegeneration to identify therapeutically relevant small molecule chemical matter against challenging targets. The strategic collaboration will aim to accelerate drug discovery in neurodegenerative disease, tackling undisclosed targets in a multi-year programme. Denali will be responsible for the further lead optimisation, development, and commercialisation of these molecules.

“We are delighted to partner with Denali Therapeutics, a company with a rigorous scientific approach and a commitment to innovation in neurodegenerative disorders”, said Dr Hannah Sore, CEO and founder of PharmEnable. “Our respective teams’ scientific and technical expertise is highly complementary, making it possible to accelerate drug discovery and bringing significant impact to patients with neurodegenerative disease.”

Under the terms of the agreement, PharmEnable will receive an upfront cash payment and will be eligible to receive development and commercial milestone payments.

“We are excited to collaborate with PharmEnable and leverage their cutting-edge AI methods with the goal of unlocking novel chemical matter in this challenging disease area,” said Dr. Alexander Schuth, Chief Operating and Financial Officer of Denali.